Aktienanalyse zu Tactile Systems Technology Inc (TCMD)TCMDTactile Systems Technology Inc

Tactile Systems Technology, Inc., doing business as Tactile Medical, is a medical technology company that manufactures and distributes medical devices for the treatment of patients with chronic diseases at home. The Company's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. It is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. It markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. It markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. It also offers Kylee, a free mobile application that helps patients learn about lymphedema. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Tactile Systems Technology Inc is a good buy right now at a current price of $23.64, especially considering its strong revenue growth of 57.60% over the past year and a solid gross margin of 75.50% in Q2 2026. The RSI is at 67.38, indicating bullish momentum, and the forward P/E ratio of 19.12 suggests it is reasonably valued compared to its growth prospects. However, the main risk is the recent decline of 13.72% year-to-date, which reflects market volatility and potential earnings challenges ahead.

6 analysts cover TCMD: 6 rate it Buy, 0 Hold and 0 Sell. The average price target is 31.67.